Synonyms: BMS-180,048 | BMS-180048 | BMS180048
Compound class:
Synthetic organic
Comment: Avitriptan (BMS-180048) is a serotonin receptor agonist with selectivity for the 5-HT1D and 5-HT1B subtypes [5]. It was investigated as an anti-mirgaine agent in the late 1990s [1-4] but never reached the market.
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
References |
1. Couch Jr JR, Saper J, Meloche JP. (1996)
Treatment of migraine with BMS180048: response at 2 hours. North American BMS180048 Study Group. Headache, 36 (9): 523-30. [PMID:8916559] |
2. Cutler NR, Salazar DE, Jhee SS, Fulmor IE, Ford N, Smith RA, Sramek JJ. (1998)
Pharmacokinetics and pharmacodynamics of avitriptan in patients with migraine after oral dosing. Headache, 38 (6): 446-52. [PMID:9664749] |
3. Dahlöf CG, Falk L, Risenfors M, Lewis CP. (1998)
Safety trial with the 5HT1B/1D agonist avitriptan (BMS-180048) in patients with migraine who have experienced pressure, tightness, and/or pain in the chest, neck, and/or throat following sumatriptan. Cephalalgia, 18 (8): 546-51. [PMID:9827246] |
4. Ryan Jr RE, Elkind A, Goldstein J. (1997)
Twenty-four-hour effectiveness of BMS 180048 in the acute treatment of migraine headaches. Headache, 37 (4): 245-8. [PMID:9150621] |
5. Saxena PR, De Vries P, Wang W, Heiligers JP, Maassen vandenBrink A, Bax WA, Yocca FD. (1997)
Effects of avitriptan, a new 5-HT 1B/1D receptor agonist, in experimental models predictive of antimigraine activity and coronary side-effect potential. Naunyn Schmiedebergs Arch Pharmacol, 355 (2): 295-302. [PMID:9050026] |